Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date
about
Overcoming therapeutic resistance in glioblastoma: the way forwardDownregulation of microRNA-504 is associated with poor prognosis in high-grade glioma.Aptamer targeting EGFRvIII mutant hampers its constitutive autophosphorylation and affects migration, invasion and proliferation of glioblastoma cells.Dinaciclib, a Cyclin-Dependent Kinase Inhibitor Promotes Proteasomal Degradation of Mcl-1 and Enhances ABT-737-Mediated Cell Death in Malignant Human Glioma Cell Lines.Identification of a peptide specifically targeting ovarian cancer by the screening of a phage display peptide libraryIntratumoral heterogeneity in glioblastoma: don't forget the peritumoral brain zone.Mir-21-Sox2 Axis Delineates Glioblastoma Subtypes with Prognostic Impact.Differentially expressed proteins in glioblastoma multiforme identified with a nanobody-based anti-proteome approach and confirmed by OncoFinder as possible tumor-class predictive biomarker candidates.miR-146b-5p functions as a tumor suppressor by targeting TRAF6 and predicts the prognosis of human gliomas.The Fallacy of Univariate Solutions to Complex Systems ProblemsThe homing and inhibiting effects of hNSCs-BMP4 on human glioma stem cells.Prognostic Value of YKL-40 in Patients with Glioblastoma: a Systematic Review and Meta-analysis.An update on the epigenetics of glioblastomas.A Dexamethasone-regulated Gene Signature Is Prognostic for Poor Survival in Glioblastoma Patients.Regulation of human glioma cell apoptosis and invasion by miR-152-3p through targeting DNMT1 and regulating NF2 : MiR-152-3p regulate glioma cell apoptosis and invasion.Patient-derived glioblastoma stem cells respond differentially to targeted therapies.AG488 as a therapy against gliomas.Blood-brain barrier crossing and breakthroughs in glioblastoma therapy.Platelets from glioblastoma patients promote angiogenesis of tumor endothelial cells and exhibit increased VEGF content and release.Mitochondrial dysfunction RAD51, and Ku80 proteolysis promote apoptotic effects of Dinaciclib in Bcl-xL silenced cells.Identification of a novel fusion gene HMGA2-EGFR in glioblastoma.Analysis of the cancer genome atlas (TCGA) database identifies an inverse relationship between interleukin-13 receptor α1 and α2 gene expression and poor prognosis and drug resistance in subjects with glioblastoma multiforme.Cancer: Keeping it real to kill glioblastoma.Identifying survival-associated modules from the dysregulated triplet network in glioblastoma multiforme.Survivin inhibitor YM155 induces mitochondrial dysfunction, autophagy, DNA damage and apoptosis in Bcl-xL silenced glioma cell lines.Co-expression of COX-2 and 5-LO in primary glioblastoma is associated with poor prognosis.Effects of Aptamer to U87-EGFRvIII Cells on the Proliferation, Radiosensitivity, and Radiotherapy of Glioblastoma Cells.Concomitant administration of radiation with eribulin improves the survival of mice harboring intracerebral glioblastoma.Comparative molecular characterization of typical and exceptional responders in glioblastoma.Epigenetic Targeting of Glioblastoma
P2860
Q29248396-EB08632D-937A-4A5A-8EAD-385F2062E694Q35145265-267ACE38-4631-4C5C-9068-7AD7CF2F690CQ35804765-E0EA6D4A-6144-4EE3-B29A-875475C5CFD7Q35846538-55004E1E-92E6-447F-A38D-2DB17856F223Q36055188-1A08EAF4-741F-4588-A8A1-5ED1DA6A2315Q36082516-2A1996D2-626C-4A47-94DA-31B305EFF527Q36272539-9230F891-DF5D-4B2C-8E15-3594B22B609BQ36370196-C6631522-8912-430D-A4DA-CDEA5B0DACF0Q36557234-92E5CC51-0BE8-4D83-863C-4D4F342597FAQ36978748-CB8937EE-3306-487A-9137-CABDC1C32E33Q37109638-E3CA020E-13A7-4560-AE9A-4AE0CF84F908Q38811271-6BF0C480-D49E-4EFD-8CF5-5CF8D386EF98Q38944047-DAA554BC-AC56-45C9-9F18-BC8F02FFD7BCQ39366720-0E6CD667-9475-4470-8C7A-94F927F35167Q41206487-0096BFD1-D3FA-44D5-AABB-B87D04FBA5F9Q42316508-31B7EB2E-254A-42F6-805A-232CED5FD2B5Q42700872-A6AE436A-1398-42DE-9A72-BF2BE062184DQ42770381-578D8477-3512-4040-B7D7-FB08BF061738Q45862300-4F8B129C-A3CB-4F39-817B-7FE789CE52A4Q47294507-1032B3E9-0955-4819-ABFB-4ED9DD5F5C0EQ47343878-FA514D8D-8380-4B7A-9FED-C25B34FBCA77Q47425171-2F9EE5E8-BB29-4E96-BA8F-DFEBC8372B0CQ48210831-985F37AA-32E9-4865-94C5-DE9F875C7D95Q48320688-9CE96D82-4BC8-4A75-BA09-3A5B9F582C60Q48445482-8CC579D3-F5F5-4DA3-BCC0-6273504C7D6EQ50859944-E936D864-A9DF-4448-BBA4-00E672B1A6E4Q52676603-E51247AD-8BB1-47B5-8B80-F00DA76AC7CFQ55457104-7DE8A49E-E18C-42B5-A25F-AB3D9A6124C5Q55474302-7DEDF6D6-65B3-46D5-B939-2B2DD8CBC22DQ58554073-F7D4058B-452E-4DAE-9DDF-A502DF794E98
P2860
Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date
description
2015 nî lūn-bûn
@nan
2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Molecular characterizations of ...... , and clinical results to date
@ast
Molecular characterizations of ...... , and clinical results to date
@en
Molecular characterizations of ...... , and clinical results to date
@nl
type
label
Molecular characterizations of ...... , and clinical results to date
@ast
Molecular characterizations of ...... , and clinical results to date
@en
Molecular characterizations of ...... , and clinical results to date
@nl
prefLabel
Molecular characterizations of ...... , and clinical results to date
@ast
Molecular characterizations of ...... , and clinical results to date
@en
Molecular characterizations of ...... , and clinical results to date
@nl
P2093
P2860
P3181
P356
P1433
P1476
Molecular characterizations of ...... , and clinical results to date
@en
P2093
Howard A. Fine
Jayson I. L. Bastien
Katharine A. McNeill
P2860
P304
P3181
P356
10.1002/CNCR.28968
P407
P577
2015-02-15T00:00:00Z